Analyst Price Targets — IMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 29, 2024 10:17 am | David Nierengarten | Wedbush | $1.33 | $1.64 | Benzinga | This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday |
| May 29, 2024 7:22 am | David Nierengarten | Wedbush | $2.00 | $1.33 | TheFly | iKena Oncology downgraded to Neutral from Outperform at Wedbush |
Latest News for IMA
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies
WASHINGTON--(BUSINESS WIRE)-- #Education--The Independent Medical Alliance (IMA) today announced the official launch of IMA Academy, a new medical education platform designed to provide healthcare professionals with expert-led, evidence-first education that is independent, transparent, and free from institutional and commercial influence. Available at academy.imahealth.org, IMA Academy represents a major milestone…
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph. D. , will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights In April 2026, the Company completed a private placement for gross proceeds…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMA.
U.S. House Trading
No House trades found for IMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.